Question 1

What are the potential side effects of HMBD-501?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors clinical trial (NCT06956690). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors clinical trial (NCT06956690). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors clinical trial (NCT06956690). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or procedures I will need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors clinical trial (NCT06956690). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors clinical trial (NCT06956690). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or if the treatment does not work?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors clinical trial (NCT06956690). Contact the study team or your healthcare provider for specific answers.

What this study is about